Review decision – August 2019
Decision to move the existing guidance to the static list
We would like to update you on the decision made regarding the review of the existing guidance on TA393; Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia and TA394; Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia.
No future changes to the commercial arrangement have been indicated at this time and there has not been any significant updates from the ODYSSEY outcomes or FOURIER trials that would change the recommendations in TA393 or TA394, therefore a review of the guidance would not provide value for the NHS.
NICE’s Guidance Executive has decided to proceed with this proposal without consultation.
Consequently, TA393 and TA394 will move to the ‘static list’ of technology appraisals.
This page was last updated: 27 August 2019